Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 20/20 | 0.86 |
| ▸ | MMP13 | P45452 | 14/20 | 0.86 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | MMP9 | P14780 | 1/20 | 0.69 |
| ▸ | MMP14 | P50281 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420941 | 1.00 | MMP12 (0.86) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3091349 | 0.93 | MMP12 (0.83) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL27540153 | 0.93 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4432986 | 0.93 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3091360 | 0.91 | MMP12 (0.72) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3078555 | 0.89 | MMP12 (0.78) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3072023 | 0.87 | MMP12 (0.75) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3073194 | 0.87 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4009639 | 0.87 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6340424 | 0.87 | MMP12 (0.80) | MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2001090361-A2 | MODULATION OF INFLAMMATION BY PROTEASE-TREATED MCP-3 CHEMOKINE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-29 | — | — | WO | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999021583-A1 | METHOD OF INHIBITING METASTASES OF CANCER CELLS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | MMP12 2774/4885MMP13 3376/4885MMP2 1658/4885 |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885MMP2 5/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | MMP12 2427/4885MMP13 4390/4885MMP2 2127/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | MMP12 3804/4885MMP13 4166/4885MMP2 2619/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.